EU-GMP: New Annex 16 Released
The European Commission has published the draft of the new EU-GMP Guideline Annex 16 "Certification by a Qualified Person and Batch Release".
As one important topic, it has been pointed out that the major task of a Qualified Person (QP) is the certification of a batch for its release. In this context, the QP must personally ensure the tasks listed chapter 3.5., and, for certain products, those listed in chapter 3.6 and 3.7. A lot of these tasks can be delegated and the QP can rely on the respective Quality Management Systems. However "the QP should have on-going assurance that this reliance is well founded" (3.5.3). Amongst these tasks are for example:
- Starting material compliance and supply chain security, including GMP assessments by third parties
- Manufacturing and testing performance
- Manufacturing and testing processes validation
- Changes and investigations completion
It is important to mention in this context that "the ultimate responsibility for the performance of an authorised medicinal product over its lifetime; its safety, quality and efficacy lies with the marketing authorisation holder (MAH). "(2.1.). "… the responsibility for ensuring that a particular batch has been manufactured in accordance with its marketing authorisation, with EU Good Manufacturing Practice (GMP), or equivalent, … lies with the QP"(2.2).
In the case that the QP has to rely on the correct functioning of the quality management system of other sites, the QP "should ensure that a written final assessment and approval of third party audit reports has been made". The QP should also "be aware of the outcome of an audit with critical impact on the product quality before certifying the relevant batches."
Another important section clarifies the role of the QP when it comes to deviations, implementing main features of the EMA Position Paper on QP Discretion (which was issued in February 2006 and updated January 2008). Chapter 5 of the draft describes the "handling of unplanned deviations". A batch with an unplanned/unexpected deviation from details contained within the Marketing Authorisation and/or GMP may be certified if a risk assessment clearly indicates that the deviation has no "adverse effect on quality, safety or efficacy of the product" (as long as the registered specifications for active substances, excipients and finished products have been met).
Stakeholders are invited to comment on this draft (150 KB) by 5 November 2013 at the latest. Comments should be sent by email to: [email protected] and [email protected]. The deadline for coming into operation is 6 months from publication.
In a special session at the 8th QP Forum from 28–29 November 2013 in Lisbon, Portugal, you will also be able to discuss this draft.
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre...
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries.
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
President Biden issues executive order to bolster U.S. biomanufacturing sector.
Decision by US drug regulator on lecanemab expected by early next year
This second facility gives the company a significant power multiplier for export capacity and geographical reach
News CPHI Discover: Remote excipient audits are on the increase, but we must do more to develop novel excipientsAhead of the session, Value Added Excipients to Unlock the Potential of APIs, at CPHI Discover on Thursday 18th May – global pharma’s largest ever virtual gathering – we spoke with one of the speakers, Dr Iain Moor...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance